Introduction
Epilepsy is one of the most common neurologic conditions and a cause of substantial morbidity and mortality. Around 50 million people around the world are likely to suffer from epilepsy 1 and its etiologies include genetic, structural, and metabolic factors. 2 Genetic factors may play a role in most cases, as either the underlying cause is primarily genetic, or there are genes that modulate the susceptibility to this disease. 3 Studies of the neurophysiologic and neurodevelopmental effects of mutations in related genes can elucidate the underlying epileptogenic mechanisms and obtained such information may help to promote the development of new treatments targeted and ways of preventing epileptogenesis. 4 Genome-wide scans and other previous studies which aimed at finding susceptibility genes for epilepsy have implicated mostly ion channel and ligand receptor genes. 5, 6 Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism as another candidate risk gene for epilepsy has been investigated for many years. MTHFR plays an important role in folate metabolism, which catalyzes the reduction of 5,10-methylenetetrahydrofolate to produce 5-methyltetrahydrofolate. The product is the dominant form of circulating folate, and provides a methyl group for the remethylation of homocysteine (Hcy) back to methionine. A common MTHFR polymorphism, 677C-T transition results in decreased enzyme activity and elevated plasma Hcy levels. 7, 8 The latter is known to cause vascular endothelial damage, 9 enhanced apoptosis, 10 DNA hypomethylation 11 and may be associated with a direct effect on neurodevelopment. 12 
MTHFR
C677T polymorphism has been associated with vascular disease, 13 congenital heart defects, 14 and some neurological diseases including Alzheimer's disease, 15 Parkinson's disease 16 and schizophrenia. 17 Previous studies also showed an association between the MTHFR C677T polymorphism and epilepsy. 5, 18, 19 Several lines of evidence suggest a role for the MTHFR C677T polymorphism as a predisposing factor for epilepsy. Lipton et al. founded that Hcy may have excitotoxicity to neurons as an agonist at the glutamate site of the N-methyl-D-aspartate (NMDA) receptors. 20 In an animal model, it was demonstrated that the NMDA receptor antagonist was protective against seizures induced by Hcy. 21 Furthermore, other studies have suggested that Hcy lowered seizure thresholds and has been exploited as a pro-convulsant in models of experimental epilepsy. 22, 23 In addition, the 677TT genotype has been identified as a risk factor for migraines with aura, 24 a condition that may share pathophysiological mechanisms with epilepsy. Hence, it is possible that the MTHFR C677T variant may be a predisposing factor for epilepsy.
18
Many previous studies have been performed to investigate the association between MTHFR C677T gene polymorphism and epilepsy susceptibility. However, the findings were inconsistent, which may be due to the limitation of individual study sample sizes. Therefore, we performed this meta-analysis including all available case-control studies to clarify the effect of MTHFR C677T polymorphism on the risk of epilepsy.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was consulted to report this review. 25 
Search strategy and selection criteria
Potentially relevant articles were selected by searching PubMed, EMBASE databases using the search terms ''MTHFR'', ''methylenetetrahydrofolate reductase'' ''C677T'', ''MTHFR C677T'', and ''epilepsy'', ''epileptic''. Related reference articles were also searched to identify other relevant publications. All researches were limited to English literatures published up to October 2013.
Inclusion and exclusion criteria
The eligible publications must meet the following inclusion criteria: (1) examining the association between MTHFR C677T polymorphism and epilepsy; (2) the study was using a casecontrol study design; (3) providing enough data on genotype frequencies of the MTHFR C677T polymorphism for calculating an odd ratio (OR) with 95% confidence interval (95% CI). The exclusion criteria included: (1) a review or case report; (2) a duplicated study. If studies contained overlapping cases and/or controls, the largest study was preferred.
Data extraction
According to the inclusion and exclusion criteria, data were extracted independently from each study by two authors (Wu and Yang) and the consensus was achieved for all data. The following information was extracted from each study included: the first author's name, year of publication, ethnicity of study population, source of controls, number of cases and controls for each genotype.
Statistical analysis
The strength of association between MTHFR C677T polymorphism and epilepsy susceptibility was assessed by ORs with 95% CIs. The pooled ORs were performed for the allele model (T vs. C), the dominant model (TT + CT vs. CC), the homozygote model (TT vs. CC) and the recessive model (TT vs. CT + CC). Moreover, a Chisquare test was used to determine whether the observed frequencies of the genotypes in the controls conformed to Hardy-Weinberg Equilibrium (HWE) expectations. Heterogeneity among the studies was quantized by the I 2 statistics.
indicated an obvious of the between-study heterogeneity, 26 the pooled OR was calculated by the random effects model; 27 otherwise, the fixed effects model was used. 28 Additionally, sensitivity analyses were performed to assess the stability of the meta-analysis results by sequential removal of each study. Finally, the Begg's tests and Egger's tests were used to analyze the publication bias. 29 All statistical analyses were conducted using Stata 9.0 (StataCrop, College Station, TX). A P value less than 0.05 was considered statistically significant.
Results

Characteristics of eligible studies
A detailed process for selecting eligible studies was shown in Fig. 1 . Based on the search criteria, a total of 81 potentially relevant publications were identified, and three of them were selected from the reference lists of the identified articles. After careful selection, 10 eligible studies 5, 18, 19, [30] [31] [32] [33] [34] [35] [36] were finally included in this metaanalysis. All control samples from included studies were in HWE. Detailed characteristics of included studies were summarized in Table 1 .
Quantitative synthesis
The heterogeneity was not significant in all the genetic models (I 2 < 50%) and the fixed effects model was therefore used in this meta-analysis. The association was detected between the MTHFR C677T polymorphism and epilepsy susceptibility in all the genetic models ( ).However, we were unable to detect any association between the MTHFR C677T polymorphism and epilepsy susceptibility in white populations.
Publication bias
The funnel plot was basically symmetric, indicating that no obvious evidence of publication bias in this meta-analysis (Supplemental Fig. S1 ). Furthermore, neither the Begg's test nor the Egger's test detected any obvious evidence of publication bias in all the genetic models ( Table 2) . 
Records idenƟfi ed from
Discussion
Many case-control studies have been performed to investigate the association between MTHFR C677T polymorphism and epilepsy, but the available evidence is still weak due to inconsistent findings among those studies. The contradictory results obtained from those studies may partly be due to a small sample size in individual studies or differences in various ethnic groups. Meta-analysis has been recognized as a useful statistical method that combines findings from independent studies to precisely evaluate the effect of selected genetic polymorphism on the risk of disease. 37 To the best of our knowledge, no meta-analysis has been conducted to assess the association between MTHFR C677T polymorphism and epilepsy. Therefore, there is a need to perform a meta-analysis using published data to clarify inconsistent findings. Based on 10 case-control studies, this meta-analysis revealed that MTHFR C677T polymorphism was associated with an increased risk of epilepsy in all genetic models. The sensitivity analyses did not substantively alter the results, indicating that results of this study were robust and reliable. T variant of the MTHFR C677T gene results in reduced MTHFR enzyme activity and elevated plasma Hcy levels. With a significant reduction in MTHFR activity, Hcy cannot be remethylated to methionine, hence accumulates within the nervous system. 38 Hcy is directly toxic to neurons and endothelial cells and can induce DNA strand breakage, oxidative stress, and apoptosis. 41 Study have shown that Nevertheless, no significant association between MTHFR A1298C polymorphism and epilepsy was detected in the subsequent studies with relatively large samples. 5, 18 However, MTHFR A1298C polymorphism is believed to have a marginal or no effect on plasma Hcy concentration. 39, 40 Consequently, this less interference with Hcy levels caused by MTHFR A1298C polymorphism might account for the lack of significant association. It would be useful to study the MTHFR A1298C polymorphism and look at polymorphisms in other genes involved in the folate metabolic pathway, but that would have increased the sample size further. Vilaseca (2000) Ono (2 000) Yoo (1999) Scher (2011) Belcastro (2010) Dean (2008) Sniezaws ka (2011 Ono (2000 ) Belcastro ( Snie zawska (20 11) Gorgo ne (20 09 In subgroup analysis stratified by ethnicity, the results revealed that the MTHFR C677T polymorphism was associated with significantly increased epilepsy susceptibility in Asian populations in all genetic models. However, this association cannot be detected in white populations in any genetic model. Hence, some potential factors may contribute to the results that the same gene polymorphism affects different ethnic populations. Firstly, the differences in genetic backgrounds may play a role. Secondly, epilepsy is a multi-factorial chronic disease with socioeconomic status, access to health care and environmental exposure such as neurocysticercosis involved in its pathophysiology. 44 It is possible that individual susceptibility in different ethnic populations may be modified by those factors. In addition, the significant association between MTHFR C677T polymorphism and epilepsy within the Asian populations may be false positive due to a small sample size. Thus, further studies with larger samples are needed to confirm the association found within this ethnic group. Several potential limitations of this meta-analysis should be acknowledged. (1) The overall outcomes were based on individual unadjusted ORs due to unavailable data, whereas a more precise estimation should be adjusted by potentially influential factors including age, gender, and environmental factors. (2) The wrong diagnosis of epilepsy occurring worldwide may contribute to the ethnic group variations in subgroup analysis. For instance, among patients diagnosed with epilepsy, 20-30% are found to have been misdiagnosed. 45, 46 Consequently, the observed effect of MTHFR C677T polymorphism may be alleviated by the incorrect diagnosis of epilepsy. (3) Although neither the funnel plots nor the Begg's test or Egger's test detected any obvious evidence of publication bias, selection bias may have occurred attributed to the fact that only English and published articles were included in this meta-analysis.
In conclusion, the present meta-analysis revealed that MTHFR C677T polymorphism was a risk factor for epilepsy in overall populations and Asian populations. However, the association between MTHFR C677T polymorphism and epilepsy could not be detected within white populations. Future studies with larger sample sizes are warranted to further confirm these findings.
